Page last updated: 2024-11-13

tiliacorinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tiliacorinine: has antineoplastic activity; isolated from Tiliacora triandra; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Tiliacoragenus[no description available]MenispermaceaeA plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. Members are mostly vines and shrubs and they contain isoquinoline alkaloids, some of which have been used as arrow poisons.[MeSH]

Cross-References

ID SourceID
PubMed CID101670430
CHEMBL ID2017489
MeSH IDM000606439

Synonyms (5)

Synonym
nsc379957 ,
tiliacorinine
C09667 ,
AC1L9CP2 ,
CHEMBL2017489 ,

Research Excerpts

Overview

Tiliacorinine is a novel multi-kinase inhibitor and possibly a potent anti-cancer agent, in cancers with high activation of EGFR.

ExcerptReferenceRelevance
"Tiliacorinine is a novel multi-kinase inhibitor and possibly a potent anti-cancer agent, in cancers with high activation of EGFR."( Induction of apoptotic cell death of cholangiocarcinoma cells by tiliacorinine from Tiliacora triandra: A mechanistic insight.
Detarya, M; Janeklang, S; Kidoikhammouan, S; Mahalapbutr, P; Pabuprapap, W; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Suksamrarn, A; Thothaisong, T; Vaeteewoottacharn, K; Waenphimai, O; Wongkham, S, 2023
)
2.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]